100129-15-5

Upstream product

• 10521-91-2 5-phenylpentan-1-ol 
• 129619-59-6 5-(4-nitrophenyl)pentanol 
• 14469-83-1 (5-bromopentyl)benzene 

Downstream Products

• 130955-67-8 (4-nitro-phenyl)-[5-(4-nitro-phenyl)-pentyl]-ether 
• 107521-40-4 1-<4-Amino-phenyl>-5-<4-amino-2-methoxy-phenoxy>-pentan 
• 143666-74-4 4-{5-[(3,4-Dimethoxy-benzyl)-methyl-amino]-pentyl}-phenylamine 
• 102017-18-5 1-(p-Nitro-phenyl)-5-(4-nitro-2-methoxy-phenoxy)-pentan 
• 110332-35-9 1-<4-Acetamino-2-methoxy-phenoxy>-5-<4-nitro-phenyl>-pentan 

Relevant academic research and scientific papers

Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using

Substituted 1,4,7-triazacyclononane-N,N′,N″-triacetic acid and 1,4,7,10-tetraazacyclcododecane-N,N′,N″,N′″-tetraacetic acid compounds with a pendant amino or hydroxyl group, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides

A number of tricyclic carboxamides have been synthesized and tested to evaluate their ability to reverse multidrug resistance in the CHRC/5 cell line.Among them the acridone derivatives were the most potent.A key feature is the presence of a dimethoxybenzyl or phenethylamine cationic site, separated from the tricyclic lipophilic part by a carbamoylphenyl chain.Optimization led to compounds 2 orders of magnitude more active than the prototype inhibitors verapamil and amiodarone.On the basis of in vitro and in vivo activities, 9,10-dihydro-5-methoxy-9-oxo-N-phenyl>-4-acridinecarboxamide (84) has been selected for further development.